An
article appearing in the Wall Street Journal (10/16, Leger,
Subscription Publication) reports on the publication's Technology Innovation
Awards. Many of the winners in this year's awards focused on improving and
saving lives, including an anti-tuberculosis initiative for India. From a pool
of 536 applications, the judges selected 37 winners and runners-up.
Vidacare Wins Bronze Award. The Wall Street Journal (10/16, Wang, Subscription
Publication) reports that Vidacare Corp. Is this year's Bronze winner of the
publication's Technology Innovation Awards. The company also won the
Medical-Devices category. Vidacare's OnControl Bone Marrow System aims to
lessen the pain of bone-marrow biopsy by allowing physicians to more precisely
and quickly perform the procedure. In a separate report (10/16), the Journal provides
additional coverage of Vidacare and the runner-ups in the medical devices
category.
Operation ASHA Wins Healthcare IT Category. The Wall Street Journal (10/16, Subscription
Publication) reports that Operation ASHA emerged the winner in the category of
healthcare IT. Operation ASHA, a nonprofit organization, utilizes grass-roots
efforts coupled with fingerprint and computer technology, to make sure that
disadvantaged people take the full course of tuberculosis medication. The
article notes that untreated tuberculosis is one of India's biggest public
health problems.
Cystic Fibrosis Treatment Wins Medicine And Biotech Category. The Wall Street Journal (10/16, Subscription
Publication) reports that Vertex Pharmaceuticals Inc.'s Kalydeco (ivacaftor)
was the winner in the Medicine and Biotech category. The medicine is meant to
treat cystic fibrosis in people that have a specific type of genetic mutation.
In the future, Kalydeco, which restores the functioning of a protein, may help
some cystic-fibrosis patients with fertility, nutrition, and bone-disease
problems.
DIA Daily is a digest of the most important news selected from
thousands of sources by the editors of BulletinHealthcare. The presence of
content or advertising does not endorse, nor imply endorsement of, any products
or services by the Drug Information Association. Neither BulletinHealthcare nor
the Drug Information Association is liable for the use of or reliance on any
information contained in this briefing.
If you would like more information about, or
have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.
Click here to check your membership status.
Drug Information
Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
No comments:
Post a Comment